TGA publishes new guidance on the GCP inspection of clinical trial sites for investigational products

The TGA has published new guidance entitled Good Clinical Practice (GCP) inspection program – Guidance for GCP inspection of clinical trial sites for investigational biologicals and medicinal products Clinical trials of medicines and biologicals regulated under the Clinical Trial Notification…

Read MoreTGA publishes new guidance on the GCP inspection of clinical trial sites for investigational products

TGA updates guidance on aspects of Australian manufacturing licences and overseas GMP certification

The TGA, Australia has updated several updated guidance documents on aspects of Australian manufacturing licences and overseas GMP certification. 1) Applying for a manufacturing licence for an Australian manufacturing site This updated step-by-step, 47 page guide (version 2.2, Dec 2021) with…

Read MoreTGA updates guidance on aspects of Australian manufacturing licences and overseas GMP certification

FDA updates on possible mitigation strategies to reduce the risk of nitrosamine drug substance-related impurities in drug products

The FDA has recently updated its information on possible mitigation strategies to reduce the risk of nitrosamine drug-substance related impurities in drug products (NDSRIs). Guidance for industry on nitrosamine was published in September 2020 and updated in February 2021. A…

Read MoreFDA updates on possible mitigation strategies to reduce the risk of nitrosamine drug substance-related impurities in drug products

Hologic launches AI based Genius Digital Diagnostics system in Europe, for cervical cancer screening

Hologic has launched its Artificial Intelligence (AI) based Genius Digital Diagnostics system in Europe, for cervical cancer screening. The burden of cervical cancer in Europe According to a study by the EPF in 2020: Current estimates indicate that every year, 61,072…

Read MoreHologic launches AI based Genius Digital Diagnostics system in Europe, for cervical cancer screening

Update on Health Canada’s Implementation of ICH’s Q12 Guideline and Pilot Programs

Health Canada has published an update on Update on the Implementation of ICH’s Q12 Guideline and Pilot Programs. What is the ICH 12 guideline about? The ICH guideline entitled, “Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management” (ICH Q12)…

Read MoreUpdate on Health Canada’s Implementation of ICH’s Q12 Guideline and Pilot Programs

Modernisation of the FDA CDER Export Certificate Program – moving to electronic CPPs (eCPPs)

The FDA CDER Export Certificate Program is being modernised, with a move soon to electronic Certificate of a Pharmaceutical Product (eCPPs). Who are the end users of CPPs? Manufacturers exporting products from the U.S. are often asked by foreign customers…

Read MoreModernisation of the FDA CDER Export Certificate Program – moving to electronic CPPs (eCPPs)

TGA update on GMP approach to overseas manufacturers of medicines and biologicals during the COVID-19 pandemic

The TGA, Australia has provided an update on its GMP approach to overseas manufacturers of medicines and biologicals during the COVID-19 pandemic. The update concerns certain temporary measures introduced in 2020 for overseas manufacturers. The following items are addressed: On-going…

Read MoreTGA update on GMP approach to overseas manufacturers of medicines and biologicals during the COVID-19 pandemic